Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.57 |
| ▸ | TSHR | P16473 | 7/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.57 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 6/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | PDE5A | O76074 | 3/20 | 0.52 |
| ▸ | BCHE | P06276 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1084049 | 0.91 | LMNA (0.69) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2231388 | 0.88 | CYP1A2 (0.69) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2232152 | 0.86 | CYP1A2 (0.66) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2232426 | 0.86 | MEN1 (0.66) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2233241 | 0.85 | MEN1 (0.65) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4868213 | 0.84 | MEN1 (0.79) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2294872 | 0.82 | MEN1 (0.61) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1083760 | 0.79 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19667644 | 0.78 | PDE5A (0.70) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1083981 | 0.78 | KDM1A (0.66) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528606-B1 | QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS | LEVITZKI ALEXANDER (IL) | 2014-09-24 | — | — | EP | disclosed |
| US-8759363-B2 | Quinazoline-based T cell proliferation inhibitors | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-06-24 | — | — | US | disclosed |
| US-20130109706-A1 | QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSALEM LTD. (IL) | 2013-05-02 | — | — | US | disclosed |
| EP-2528606-A1 | QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011092695-A1 | QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109706-A1 | QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS | IL2, CD4, NFATC1 | MEN1 3730/4885KMT2A 1486/4885CYP1A2 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.